Management

Robert Igarashi, Ph.D.
President and Co-Founder

Read Bio

Robert Igarashi, Ph.D. is the president and co-founder of CytoSen Therapeutics. Dr. Igarashi has a diverse background in life sciences and has played an instrumental role in the development of the particle based natural killer (NK) cell stimulating technology. He has brought his biochemical and physico-chemical expertise to combine with immunology for developing and refining the nanoparticle based method for NK cell stimulation that could be used for ex vivo expansion as well as in vivo stimulation of therapeutic NK cells.He has been crucial in understanding the biochemical aspects of the plasma membrane particles interacting with NK cells and how they can be further innovated to add novel therapeutic dimensions for adoptive NK cell therapy.

Dr. Igarashi joined the faculty at the University of Central Florida as an assistant professor in the Department of Chemistry with a joint appointment in the Burnett School of Biomedical Sciences. He is now a research scientist developing innovative methods for NK cell therapies. Dr. Igarashi achieved his B.S. and M.S. in biochemistry at California State University Fullerton and Ph.D. in biochemistry at Utah State University and was a postdoctoral scholar at University of California, Berkeley.

Trent Carrier, Ph.D.
Chief Operating Officer

Read Bio

Trent Carrier, Ph.D. is the Chief Operating Officer of CytoSen Therapeutics. Dr. Carrier has extensive expertise in multiple biotherapeutic platforms and more than 20 years of scientific, business, and executive management experience in the biotechnology industry. He joined CytoSen from Takeda Vaccines where he served as Vice President of Vaccine Technology and Engineering where he worked on vaccines for norovirus and dengue virus. Prior to Takeda, Dr. Carrier was the Chief Business Officer at Biologics Consulting Group, a regulatory and product development consulting firm. Prior to that, Dr. Carrier served as the Head of Cellular Medicine at Life Technologies, where he had responsibility for the Cell Therapy Systems (CTS TM) product portfolio. Dr. Carrier received his Ph.D. in chemical engineering from the University of California, Berkeley and his MBA from the Darden School of Business at the University of Virginia.

Joseph S. Shan
Head of Clinical and Regulatory Affairs

Read Bio

Joseph S. Shan is Head of Clinical and Regulatory Affairs at CytoSen Therapeutics, where he is leading clinical development and regulatory submissions. Previously, Mr. Shan served as Vice President, Clinical and Regulatory Affairs at Peregrine Pharmaceuticals, where he was responsible for the design and execution of clinical trials and overseeing regulatory submissions. At Peregrine, he was instrumental in advancing the clinical development from pre-IND through Phase 3 clinical trials of the Company’s immuno-oncology candidates. Prior to Peregrine, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards Lifesciences (formerly Baxter CardioVascular Group) and Sulzer Medica. Mr. Shan received his B.S. degree in physiological sciences from the University of California, Los Angeles and his MPH degree from the George Washington University in Washington, D.C. He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals, and the Regulatory Affairs Professionals Society.

Dennis J. Jameson
Advisor

Read Bio

Dennis J. Jameson brings more than forty years of experience in building successful businesses while serving in C-level financial and management roles in both public and private companies. For CytoSen, Mr. Jameson is advising on administrative, audit and regulatory compliance. He currently serves as Chief Operating Officer (COO) for Appliance Innovation, Inc. Prior to this role, he served as president of a private company, where he led substantial revenue growth and eventually managed the sale of the company. Mr. Jameson has also held the position of Chief Financial Officer for NASDAQ-listed TurboChef Technologies, Inc. Mr. Jameson holds a B.S. degree in account ing from the University of Kentucky.